Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016
Published Jun 30, 2016
49 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016, provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
- The report reviews Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
- Identify the use of d

  
Source:
Document ID
GMDHC0112TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Overview61
Therapeutics Development73
  Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Stage of Development71
  Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Therapy Area81
  Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Indication91
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Products under Development by Companies122
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Therapeutics Assessment144
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration161
  Assessment by Molecule Type171
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Companies Involved in Therapeutics Development185
  Amura Holdings Limited181
  Medivir AB191
  Merck &Co., Inc.201
  Virobay Inc.211
  Wroclawskie Centrum Badan EIT+ Sp. z o.o.221
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Drug Profiles2310
  AM-3701 Drug Profile231
  AM-3876 Drug Profile241
  MIV-711 Drug Profile252
  odanacatib Drug Profile273
  Small Molecules to Inhibit CTSK for Oncology Drug Profile301
  VBY-129 Drug Profile311
  VBY-285 Drug Profile321
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Dormant Projects331
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Discontinued Products341
Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Featured News &Press Releases3513
  Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis351
  Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis352
  Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders371
  May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting381
  Oct 13, 2012: Merck Announces Results From Phase II Clinical Trial Of Odanacatib In Post-Menopausal Osteoporosis391
  Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders401
  Jul 11, 2012: Merck Provides Update On Phase III Trial Of Odanacatib For Treatment Of Osteoporosis401
  May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders411
  Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711421
  Sep 19, 2011: Merck Announces Presentation Of New Data On Odanacatib Phase III Investigational Cat-K Inhibitor For Osteoporosis At Annual Meeting Of American Society For Bone And Mineral Research422
  Oct 18, 2010: Merck Presents New Data On Odanacatib For Treatment of Osteoporosis In Postmenopausal Women at ASBMR Annual Meeting441
  Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA451
  Sep 14, 2009: New, Long-Term Data For Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results In Treating Osteoporosis461
  Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711461
  Sep 16, 2008: Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years At Key Fracture Sites In Phase IIB Study462
Appendix482
  Methodology481
  Coverage481
  Secondary Research481
  Primary Research481
  Expert Panel Validation481
  Contact Us481
  Disclaimer491

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cathepsin-K-Cathepsin-O-or-Cathepsin-X-or-EC-3-4-22-38-Pipeline-Review-H1-2016-2088-16073>
  
APA:
Global Markets Direct - Market Research. (2016). Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cathepsin-K-Cathepsin-O-or-Cathepsin-X-or-EC-3-4-22-38-Pipeline-Review-H1-2016-2088-16073>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.